Breaking News

Today Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Conference/Events	Vincerx Pharma to hold a Key Opinion Leader conference call » 10:07 04/16/21 04/16 10:07 04/16/21 10:07 VINC Vincerx Pharma $18.40 / +0.125 (+0.68%) Dr. Druker of Knight… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VINC Vincerx Pharma $18.40 / +0.125 (+0.68%) 04/11/21 Vincera Pharma presents preclinical data on VIP236 at AACR Meeting 04/07/21 Vincera Pharma to host KOL webinar on bioconjugation, CDK9 inhibitors 04/01/21 Vincera Pharma announces formation of Scientific Advisory Board 03/02/21 Vincera Pharma appoints Hermes Garban as CMO, Hans-Georg Lerchen as CSO VINC Vincerx Pharma $18.40 / +0.125 (+0.68%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan VINC Vincerx Pharma $18.40 / +0.125 (+0.68%) 03/23/21 Vincera Pharma reports 2020 EPS ($2.04), two est. ($1.82) 12:00 Today Vincerx Pharma - VINC

Sunday
Hot Stocks	Vincera Pharma presents preclinical data on VIP236 at AACR Meeting » 17:10 04/11/21 04/11 17:10 04/11/21 17:10 VINC Vincera Pharma $19.05 / +0.03 (+0.16%) Vincerx Pharma presented… Vincerx Pharma presented preclinical data characterizing VIP236, a novel small molecule drug conjugate at the American Association for Cancer Research Annual Meeting 2021. The SMDC is comprised of an alphavbeta3 integrin antagonist linked to a cytotoxic camptothecin derivative, designed to selectively release its payload via neutrophil elastase in the tumor microenvironment. VIP236 is a novel SMDC targeted by an alphavbeta3 integrin antagonist with a neutrophil elastase cleavable linker linked to a modified CPT payload derived from SN38, a well-known cytotoxic drug and active metabolite of irinotecan. Efficient anti-tumor targeting and greater cytotoxicity is achieved by multiple mechanisms associated with aggressive tumor cells and its microenvironment. VIP236 targets alphavbeta3 integrin which is overexpressed by invasive cancer and stromal cells in the TME such as endothelial cells undergoing neovascularization. Efficient tumor homing with the alphavbeta3 integrin antagonist is demonstrated by the imaging studies. Neutrophil elastase is overexpressed in the invasive TME associated with advanced cancers. The abundance of NE in the TME promotes linker cleavage, release of the active modified CPT payload and enhances VIP236 cytotoxicity. Drug resistant cancer cells often have greater drug efflux capabilities. The CPT payload is modified to improve cellular permeability and lower cell efflux properties resulting in better cytotoxicity in cancer cells overexpressing drug efflux pumps when compared to SN38. The combination of these properties results in a 10.8-fold higher tumor-to-plasma ratio of the targeted and modified CPT payload compared to administration of the payload alone. In vivo, VIP236 demonstrates higher antitumor efficacy in comparison to reference chemotherapy drugs across multiple mouse xenograft models. Complete tumor responses were observed in 100% of mice across all dose levels in the MX-1 triple negative breast cancer model. Partial responses were observed in 100% of mice in both the NCI-H69 small cell lung cancer and SW480 colorectal cancer mouse models at a VIP236 dose of 40mg/kg. Across mouse models, VIP236 showed good tolerability as evidenced by less than 5% mean body weight loss. ShowHide Related Items >><< Company News Street Research Earnings VINC Vincera Pharma $19.05 / +0.03 (+0.16%) 04/07/21 Vincera Pharma to host KOL webinar on bioconjugation, CDK9 inhibitors 04/01/21 Vincera Pharma announces formation of Scientific Advisory Board 03/02/21 Vincera Pharma appoints Hermes Garban as CMO, Hans-Georg Lerchen as CSO 02/24/21 Vincera Pharma to host KOL webinar on VIP152 VINC Vincera Pharma $19.05 / +0.03 (+0.16%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan VINC Vincera Pharma $19.05 / +0.03 (+0.16%) 03/23/21 Vincera Pharma reports 2020 EPS ($2.04), two est. ($1.82)

Over a week ago
Hot Stocks	Vincera Pharma to host KOL webinar on bioconjugation, CDK9 inhibitors » 08:18 04/07/21 04/07 08:18 04/07/21 08:18 VINC Vincera Pharma $18.91 / -0.34 (-1.77%) Vincerx Pharma announced… Vincerx Pharma announced that it will be hosting a key opinion leader meeting on bioconjugation and CDK9 inhibitors for the treatment of hematologic and solid tumors on Friday, April 16, 2021 at 12:00 PM ET. The event will feature presentations by KOLs Brian Druker, M.D., Knight Cancer Institute, and Anthony W. Tolcher, M.D., NEXT Oncology. Dr. Tolcher will discuss tackling normal tissue toxicity from antibody-drug conjugates and Dr. Druker will discuss CDK9 in hematologic malignancies. Drs. Druker and Tolcher will be available to answer questions following the formal presentations. Vincerx's management team will discuss its poster titled, "A novel small molecule drug conjugate -alphavbeta3 integrin antagonist linked to a cytotoxic camptothecin derivative- for the treatment of multiple cancer types," which will be presented at the upcoming American Association for Cancer Research Annual Meeting, as well as the Company's bioconjugation platform. Vincerx's preclinical bioconjugation platform seeks to address the current limitations of small-molecule and antibody-drug conjugates in oncology and consists of VIP236, a small molecule drug conjugate targeting advanced and metastatic cancer, as well as VIP943 and VIP924, two ADCs targeting hematologic tumors. ShowHide Related Items >><< Company News Street Research Earnings VINC Vincera Pharma $18.91 / -0.34 (-1.77%) 04/01/21 Vincera Pharma announces formation of Scientific Advisory Board 03/02/21 Vincera Pharma appoints Hermes Garban as CMO, Hans-Georg Lerchen as CSO 02/24/21 Vincera Pharma to host KOL webinar on VIP152 01/07/21 Vincera Pharma changes name to Vincerx VINC Vincera Pharma $18.91 / -0.34 (-1.77%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan VINC Vincera Pharma $18.91 / -0.34 (-1.77%) 03/23/21 Vincera Pharma reports 2020 EPS ($2.04), two est. ($1.82)
Hot Stocks	Vincera Pharma announces formation of Scientific Advisory Board » 08:08 04/01/21 04/01 08:08 04/01/21 08:08 VINC Vincera Pharma $19.36 / +0.06 (+0.31%) Vincerx Pharma announced… Vincerx Pharma announced the formation of its Scientific Advisory Board composed of world leading academics and industry leaders in cancer research and therapeutics. John Byrd, M.D., will serve as Chairman of the SAB. Vincerx's SAB is comprised of: John Byrd. Byrd is an internationally known researcher and clinical specialist in leukemia and other hematologic malignancies at Ohio State's Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, where he serves as Senior Advisor for Cancer Experimental Therapeutics. Howard A. "Skip" Burris III, M.D., FASCO, FACP. Burris serves as President and Chief Medical Officer of Sarah Cannon, as well as the Executive Director, drug development for Sarah Cannon Research Institute. Gerard Evan, Ph.D. Dr. Evan is the Sir William Dunn Professor and Head of Biochemistry at the University of Cambridge. Ian W. Flinn, M.D., Ph.D. Dr. Flinn is an internationally recognized clinical investigator whose research focuses on the development of new therapies for patients with lymphoma and chronic lymphocytic leukemia. Andre Goy, M.D., M.S. Dr. Goy is an internationally renowned clinician and researcher of all types of lymphoma, including Hodgkin's disease, non-Hodgkin's lymphoma including aggressive lymphoma and mantle cell lymphoma, and HIV-associated lymphoma. As Physician in Chief for Hackensack Meridian Health Oncology Services and Chairman of John Theurer Cancer Center at Hackensack University Medical Center as well as Founding Chair of Oncology at the Hackensack Meridian Health School of Medicine, he leads New Jersey's largest program for research, treatment and management of lymphoma. Rosa Lapalombella, Ph.D. Dr. Lapalombella, Assistant Professor at The Ohio State University, has a strong history of translational medical research. Anthony W. Tolcher, M.D., FRCPS, FACP. Dr. Tolcher is CEO and Founder of NEXT Oncology. ShowHide Related Items >><< Company News Street Research Earnings VINC Vincera Pharma $19.36 / +0.06 (+0.31%) 03/02/21 Vincera Pharma appoints Hermes Garban as CMO, Hans-Georg Lerchen as CSO 02/24/21 Vincera Pharma to host KOL webinar on VIP152 01/07/21 Vincera Pharma changes name to Vincerx 12/23/20 Vincera Pharma comples business combination with LifeSci Acquisition VINC Vincera Pharma $19.36 / +0.06 (+0.31%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan VINC Vincera Pharma $19.36 / +0.06 (+0.31%) 03/23/21 Vincera Pharma reports 2020 EPS ($2.04), two est. ($1.82)
Earnings	Vincera Pharma reports 2020 EPS ($2.04), two est. ($1.82) » 08:05 03/23/21 03/23 08:05 03/23/21 08:05 VINC Vincera Pharma $23.30 / -1.44 (-5.82%) "Over the past… "Over the past months, Vincerx has completed transformative milestones; licensing a compelling oncology pipeline from Bayer, launching as a public company, and strengthening our already proven leadership team," said Ahmed Hamdy M.D., CEO of Vincerx. "These accomplishments, in combination with our strong balance sheet, leave us well positioned as we prepare to launch Phase 1b studies of VIP152, our highly selective and potent CDK9 inhibitor, in Myc-driven hematologic malignancies and solid tumors, as well as relapsed/refractory chronic lymphocytic leukemia. With robust preclinical on-mechanism activity, and compelling early signals of Phase 1 clinical activity in challenging patient populations, including those with double-hit DLBCL, we are confident that VIP152 represents a compelling and differentiated opportunity. In addition to this clinical progress, we have in parallel continued to develop our preclinical bioconjugation platform, consisting of our next-generation antibody-drug conjugates which have the potential to overcome limitations of currently approved ADCs and our innovative small molecule drug conjugate, which will have data presented at AACR. We are excited to embark on this new phase of development and look forward to continued execution in 2021 across our strategic clinical program with VIP152, a potential best-in-class asset with multiple Accelerated Approval opportunities." ShowHide Related Items >><< Company News Street Research On The Fly VINC Vincera Pharma $23.30 / -1.44 (-5.82%) 03/02/21 Vincera Pharma appoints Hermes Garban as CMO, Hans-Georg Lerchen as CSO 02/24/21 Vincera Pharma to host KOL webinar on VIP152 01/07/21 Vincera Pharma changes name to Vincerx 12/23/20 Vincera Pharma comples business combination with LifeSci Acquisition VINC Vincera Pharma $23.30 / -1.44 (-5.82%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan VINC Vincera Pharma $23.30 / -1.44 (-5.82%) 09/29/20 Fly Intel: Wall Street's top stories at midday

Over a month ago
Conference/Events	Vincera Pharma to host business news update conference call » 11:25 03/05/21 03/05 11:25 03/05/21 11:25 VINC Vincera Pharma $18.00 / -1.17 (-6.10%) Management, along with… Management, along with Key Opinion Leaders Ian Flinn, MD, PhD, John Byrd, MD and Howard Burns, III MD, discuss the CDK9 inhibitor landscape in hematologic and solid tumors, as well as Vincerx's lead product, VIP152 a CDK9 inhibitor optimized for intermittent intravenous treatment on a conference call to be held on March 5 at 12 pm. Webcast Link ShowHide Related Items >><< Company News Street Research On The Fly Events VINC Vincera Pharma $18.00 / -1.17 (-6.10%) 03/02/21 Vincera Pharma appoints Hermes Garban as CMO, Hans-Georg Lerchen as CSO 02/24/21 Vincera Pharma to host KOL webinar on VIP152 01/07/21 Vincera Pharma changes name to Vincerx 12/23/20 Vincera Pharma comples business combination with LifeSci Acquisition VINC Vincera Pharma $18.00 / -1.17 (-6.10%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan VINC Vincera Pharma $18.00 / -1.17 (-6.10%) 09/29/20 Fly Intel: Wall Street's top stories at midday 03/05/21 Vincera Pharma - VINC
Conference/Events	Vincera Pharma to host business news update conference call » 07:58 03/05/21 03/05 07:58 03/05/21 07:58 VINC Vincera Pharma $19.16 / -1.26 (-6.17%) Management, along with… Management, along with Key Opinion Leaders Ian Flinn, MD, PhD, John Byrd, MD and Howard Burns, III MD, discuss the CDK9 inhibitor landscape in hematologic and solid tumors, as well as Vincerx's lead product, VIP152 a CDK9 inhibitor optimized for intermittent intravenous treatment on a conference call to be held on March 5 at 12 pm. Webcast Link ShowHide Related Items >><< Company News Street Research On The Fly Events VINC Vincera Pharma $19.16 / -1.26 (-6.17%) 03/02/21 Vincera Pharma appoints Hermes Garban as CMO, Hans-Georg Lerchen as CSO 02/24/21 Vincera Pharma to host KOL webinar on VIP152 01/07/21 Vincera Pharma changes name to Vincerx 12/23/20 Vincera Pharma comples business combination with LifeSci Acquisition VINC Vincera Pharma $19.16 / -1.26 (-6.17%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan VINC Vincera Pharma $19.16 / -1.26 (-6.17%) 09/29/20 Fly Intel: Wall Street's top stories at midday 03/05/21 Vincera Pharma - VINC
Hot Stocks	Vincera Pharma appoints Hermes Garban as CMO, Hans-Georg Lerchen as CSO » 08:06 03/02/21 03/02 08:06 03/02/21 08:06 VINC Vincera Pharma $19.24 / +0.23 (+1.21%) Vincerx Pharma announced… Vincerx Pharma announced the addition of three new executives to the company's management team. Hermes Garban, M.D., Ph.D. has been appointed as Chief Medical Officer, Hans-Georg Lerchen, Ph.D. has been appointed as Chief Scientific Officer, and Tom Thomas, has been appointed as General Counsel and Chief Legal Officer of Vincerx. Hermes Garban, M.D., Ph.D. is the Chief Medical Officer of Vincerx Pharma, Inc. Before joining Vincerx, Dr. Garban served as Head, Therapeutics Discovery and Development at ImmunityBio, Inc., a registration stage immuno-oncology and infectious disease company responsible for conducting Phase 1 through Phase 3 clinical trials focusing on solid tumors and immunotherapies development, from March 2019 to February 2021. Hans-Georg Lerchen, Ph.D. is the Chief Scientific Officer of Vincerx. Before joining Vincerx, Dr. Lerchen was a Distinguished Fellow in the Bayer Science Fellow Network of the Pharmaceuticals R&D organization of Bayer AG. Tom Thomas will be joining as General Counsel and Chief Legal Officer of Vincerx on March 15. Mr. Thomas is a partner at Pillsbury Winthrop Shaw Pittman LLP, a leading international law firm with offices in major metropolitan centers around the world. ShowHide Related Items >><< Company News Street Research On The Fly Events VINC Vincera Pharma $19.24 / +0.23 (+1.21%) 02/24/21 Vincera Pharma to host KOL webinar on VIP152 01/07/21 Vincera Pharma changes name to Vincerx 12/23/20 Vincera Pharma comples business combination with LifeSci Acquisition VINC Vincera Pharma $19.24 / +0.23 (+1.21%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan VINC Vincera Pharma $19.24 / +0.23 (+1.21%) 09/29/20 Fly Intel: Wall Street's top stories at midday 03/05/21 Vincera Pharma - VINC
Conference/Events	SVB Leerink to hold a virtual conference » 04:55 02/26/21 02/26 04:55 02/26/21 04:55 ACRS Aclaris Therapeutics $21.24 / +0.52 (+2.51%) , BBIO BridgeBio $65.26 / -2.3001 (-3.40%) , HLIO Helios Technologies $65.84 / -1.11 (-1.66%) , MTCR Metracrine $8.57 / -0.24 (-2.72%) , SIEN Sientra $7.70 / -0.355 (-4.41%) , TRVI Trevi Therapeutics $2.82 / -0.07 (-2.42%) , VCYT Veracyte $58.71 / -3.635 (-5.83%) , VINC Vincera Pharma $19.19 / -0.92 (-4.57%) , CTSO CytoSorbents $9.70 / -0.44 (-4.34%) , CTLT Catalent $112.25 / -2.87 (-2.49%) , IMRA Imara $12.49 / -0.45 (-3.48%) , ITOS iTeos Therapeutics $41.77 / +0.77 (+1.88%) , LLY Eli Lilly $203.91 / -0.735 (-0.36%) , AUPH Aurinia Pharmaceuticals $14.59 / +0.015 (+0.10%) , AVXL Anavex $13.01 / +0.65 (+5.26%) , DRIO DarioHealth $27.17 / -2.22 (-7.55%) , ENTA Enanta $50.58 / -1.1548 (-2.23%) , EQ Equillium $7.65 / -0.22 (-2.80%) , EXEL Exelixis $21.96 / -0.73 (-3.22%) , SDGR Schrodinger $104.43 / -6.46 (-5.83%) 10th Annual Global… 10th Annual Global Healthcare Virtual Conference will be held on February 22-26. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VINC VCYT TRVI SIEN SDGR MTCR LLY ITOS IMRA HLIO EXEL EQ ENTA DRIO CTSO CTLT BBIO AVXL AUPH ACRS VINC Vincera Pharma $19.19 / -0.92 (-4.57%) 02/24/21 Vincera Pharma to host KOL webinar on VIP152 01/07/21 Vincera Pharma changes name to Vincerx 12/23/20 Vincera Pharma comples business combination with LifeSci Acquisition VCYT Veracyte $58.71 / -3.635 (-5.83%) 02/03/21 Veracyte to acquire Decipher Biosciences for $600M 12/22/20 Bayer, Veracyte announce new collaboration to advance precision oncology 12/21/20 Veracyte receives ISO certification for QMS 12/15/20 Veracyte announces expansion of collaboration of lung cancer initiative at JNJ TRVI Trevi Therapeutics $2.82 / -0.07 (-2.42%) 02/01/21 Trevi Therapeutics appoints William Forbes as Chief Development Officer 10/21/20 Trevi Therapeutics resumes patient screening for Phase 2 trial of Haduvio SIEN Sientra $7.70 / -0.355 (-4.41%) 11/23/20 Sientra receives approval for Sientra OPUS silicone gel breast implant sizer 11/09/20 Sientra names Ron Menezes CEO, Jeffrey Nugent to retire SDGR Schrodinger $104.43 / -6.46 (-5.83%) 02/25/21 Schrodinger expands collaboration with Google Cloud 02/24/21 Schrodinger holder David Shaw sells 457.7K shares of common stock 01/19/21 David E Shaw reports 17.2% passive stake in Schrodinger 12/07/20 Schrodinger presents data from MALT1 inhibitor program at ASH MTCR Metracrine $8.57 / -0.24 (-2.72%) 02/16/21 Metracrine announces publication of results from Phase 1b study of MET409 01/19/21 Metracrine's MET642 granted Fast Track designation by FDA 01/05/21 Metracrine treats first patient in Phase 2a trial of MET409 with Jardiance 12/17/20 Metracrine's MET642 reports positive efficacy and safety Phase 1 results LLY Eli Lilly $203.91 / -0.735 (-0.36%) 02/25/21 Eli Lilly, Welldoc announce agreement to create insulin management solution 02/23/21 Veru submits NDA for proprietary TADFIN for BPH 02/18/21 Eli Lilly, Rigel Pharmaceuticals enter exclusive license agreement for R552 02/17/21 Eli Lilly announces SURPASS-3, SURPASS-5 trials meet primary endpoints ITOS iTeos Therapeutics $41.77 / +0.77 (+1.88%) 11/12/20 iTeos Therapeutics appoints Matthew Roden to board of directors IMRA Imara $12.49 / -0.45 (-3.48%) 01/20/21 Imara appoints Kenneth Atttie as Chief Medical Officer 01/06/21 Imara reports Phase 2a trial results of IMR-687 in SCD 12/07/20 Imara presents IMR-687 Phase 2a OLE case reports 11/30/20 Imara to present clinical data on IMR-687 at ASH Annual Meeting HLIO Helios Technologies $65.84 / -1.11 (-1.66%) 01/21/21 Helios Technologies to acquire BJN Technologies, terms undisclosed 10/12/20 Helios Technologies to acquire Balboa Water Group for $218.5M EXEL Exelixis $21.96 / -0.73 (-3.22%) 02/25/21 Exelixis announces Breakthrough Therapy Designation granted to cabozantinib 02/14/21 Exelixis announces Phase 2 results for CABOMETYX in metastatic PRCC 02/12/21 Exelixis announces 'positive' final data for Phase 1 cabozantinib trial 02/08/21 Exelixis to announce results from Cabometyx retrospective analysis EQ Equillium $7.65 / -0.22 (-2.80%) 02/12/21 Equillium presents 'positive' interim clinical data on Itolizumab trial in aGVHD 02/09/21 Equillium appoints Katherine Xu to board of directors 12/21/20 Equillium appoints Dolca Thomas as CMO, EVP, R&D 12/07/20 Equillium presents translational data on itolizumab ENTA Enanta $50.58 / -1.1548 (-2.23%) 01/08/21 Enanta says 'meaningful progress' made on pipeline in 2020 09/14/20 Enanta initiates Phase 1 clinical study of EDP-297 08/28/20 Enanta to present data from hepatitis B virus, NASH programs at EASL DRIO DarioHealth $27.17 / -2.22 (-7.55%) 01/27/21 DarioHealth to acquire Upright Technologies for $29.5M in stock, $1.5M in cash 12/22/20 DarioHealth enters into agreement with Presbyterian Medical Services 11/24/20 DarioHealth to offer therapeutics solution to Fortune 500 technology companies 09/21/20 DarioHealth, HMC HealthWorks announce partnership agreement CTSO CytoSorbents $9.70 / -0.44 (-4.34%) 01/19/21 CytoSorb approved in Korea for all EU approved indications 01/12/21 Health Canada authorizes CytoSorb for use in hospitalized COVID-19 patients 01/04/21 CytoSorbents gets Medical Device Authorization for CytoSorb in COVID-19 patients 12/09/20 CytoSorbents announces publication of CytoSorb matched analysis CTLT Catalent $112.25 / -2.87 (-2.49%) 02/16/21 Moderna provides supply update for U.S. COVID-19 vaccines 02/02/21 Catalent reports Q2 adjusted EPS 63c, consensus 55c 01/13/21 Catalent to acquire manufacturing operations from Acorda Therapeutics 01/13/21 Acorda to sell Inbrija manufacturing operations to Catalent for $80M BBIO BridgeBio $65.26 / -2.3001 (-3.40%) 02/19/21 BridgeBio, ML Bio Solutions dose first patient in Phase 2 trial of BBP-418 02/02/21 BridgeBio doses first patient in Phase 1/2 trial of BBP-681 for malformations 01/26/21 BridgeBio completes acquisition of Eidos Therapeutics 01/19/21 BridgeBio and Eidos' stockholders approve acquisition AVXL Anavex $13.01 / +0.65 (+5.26%) 02/11/21 Anavex sees sufficient cash runway for up to three years 02/04/21 Anavex trading resumes 02/04/21 Anavex trading halted, volatility trading pause 02/03/21 Anavex trading resumes AUPH Aurinia Pharmaceuticals $14.59 / +0.015 (+0.10%) 01/24/21 FDA approves Aurinia's LUPKYNIS for adult patients with active lupus nephritis 01/22/21 Aurinia Pharmaceuticals trading halted, news pending 12/17/20 Aurinia Pharmaceuticals enters voclosporin license agreement with Otsuka 12/15/20 Aurinia, Lonza strike exclusive pact for voclosporin manufacturing capacity ACRS Aclaris Therapeutics $21.24 / +0.52 (+2.51%) 02/25/21 Aclaris Therapeutics sees cash, equivalents funding operations through 2023E 02/22/21 Aclaris Therapeutics trading resumes 02/22/21 Aclaris Therapeutics trading halted, volatility trading pause 01/21/21 Aclaris gets orphan drug designation in cryopyrin-associated periodic syndrome ACRS BBIO HLIO MTCR SIEN TRVI VCYT VINC CTSO CTLT IMRA ITOS LLY AUPH AVXL DRIO ENTA EQ EXEL SDGR ACRS Aclaris Therapeutics $21.24 / +0.52 (+2.51%) 02/02/21 Cantor Fitzgerald Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald 01/19/21 William Blair Aclaris has potential in range of 'blockbuster indications,' says William Blair BBIO BridgeBio $65.26 / -2.3001 (-3.40%) 02/22/21 JPMorgan BridgeBio reinstated with an Overweight at JPMorgan 02/09/21 Fly Intel: Top five analyst initiations 02/09/21 Goldman Sachs BridgeBio reinstated with a Buy at Goldman Sachs 01/11/21 H.C. Wainwright BridgeBio price target raised to $87 from $64 at H.C. Wainwright HLIO Helios Technologies $65.84 / -1.11 (-1.66%) 10/12/20 Baird Helios Technologies upgraded to Outperform from Neutral at Baird 05/29/20 Morgan Stanley Morgan Stanley upgrades Helios to Equal Weight following underperformance 05/29/20 Morgan Stanley Helios Technologies upgraded to Equal Weight from Underweight at Morgan Stanley 03/27/20 Truist Helios Technologies price target lowered to $36 from $45 at SunTrust MTCR Metracrine $8.57 / -0.24 (-2.72%) 10/12/20 Canaccord Metracrine initiated with a Buy at Canaccord 10/12/20 Jefferies Metracrine initiated with a Buy at Jefferies 10/12/20 RBC Capital Metracrine initiated with an Outperform at RBC Capital SIEN Sientra $7.70 / -0.355 (-4.41%) 02/05/21 Canaccord Sientra price target raised to $8 from $6 at Canaccord 10/08/20 Stifel Stifel sees upside potential for Sientra after survey of aesthetics doctors 06/11/20 Maxim Sientra price target raised to $8 from $5 at Maxim 03/12/20 Craig-Hallum Sientra price target lowered to $9 from $14 at Craig-Hallum TRVI Trevi Therapeutics $2.82 / -0.07 (-2.42%) 07/13/20 Stifel Trevi Therapeutics price target lowered to $10 from $14 at Stifel VCYT Veracyte $58.71 / -3.635 (-5.83%) 02/18/21 Needham Veracyte assumed with a Buy at Needham 02/08/21 SVB Leerink Veracyte price target raised to $83 from $40 at SVB Leerink 01/27/21 Truist Veracyte initiated with a Buy at Truist 12/17/20 Lake Street Veracyte price target raised to $60 from $40 at Lake Street VINC Vincera Pharma $19.19 / -0.92 (-4.57%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan CTSO CytoSorbents $9.70 / -0.44 (-4.34%) 01/04/21 B. Riley CytoSorbents price target raised to $17 from $16 at B. Riley Securities 09/01/20 SVB Leerink CytoSorbents initiated with an Outperform at SVB Leerink 08/25/20 B. Riley CytoSorbents 29% pullback from highs a buying opportunity, says B. Riley FBR 06/02/20 B. Riley CytoSorbents gaining relevance as COVID-19 treatment, says B. Riley FBR CTLT Catalent $112.25 / -2.87 (-2.49%) 02/03/21 UBS Catalent price target raised to $135 from $115 at UBS 02/03/21 RBC Capital Catalent price target raised to $137 from $125 at RBC Capital 01/08/21 JPMorgan Catalent price target raised to $130 from $110 at JPMorgan 01/04/21 Stephens Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens IMRA Imara $12.49 / -0.45 (-3.48%) 01/06/21 SVB Leerink Imara selloff a potential buying opportunity, says SVB Leerink 08/17/20 Fly Intel: Top five analyst upgrades 08/17/20 Citi Imara upgraded to Buy from Neutral at Citi 06/30/20 Citi Imara downgraded to Neutral from Buy at Citi ITOS iTeos Therapeutics $41.77 / +0.77 (+1.88%) 10/07/20 Baird iTeos Therapeutics initiated with an Outperform at Baird 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/01/20 Piper Sandler iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler 08/18/20 SVB Leerink SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform LLY Eli Lilly $203.91 / -0.735 (-0.36%) 02/18/21 H.C. Wainwright Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright 02/18/21 Piper Sandler Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler 02/12/21 Cowen Eli Lilly price target raised to $235 from $195 at Cowen 02/08/21 SVB Leerink AbCellera price target raised to $52 from $45 at SVB Leerink AUPH Aurinia Pharmaceuticals $14.59 / +0.015 (+0.10%) 01/26/21 RBC Capital Aurinia Pharmaceuticals price target raised to $28 from $20 at RBC Capital 01/26/21 Cantor Fitzgerald Aurinia Pharmaceuticals price target raised to $34 from $27 at Cantor Fitzgerald 01/25/21 Oppenheimer Aurinia Pharmaceuticals price target raised to $28 from $20 at Oppenheimer 01/25/21 H.C. Wainwright Aurinia Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright AVXL Anavex $13.01 / +0.65 (+5.26%) 02/24/21 Cantor Fitzgerald Anavex price target raised to $25 from $10 at Cantor Fitzgerald 02/23/21 Cantor Fitzgerald Anavex price target raised to $25 from $10 at Cantor Fitzgerald 12/29/20 Cantor Fitzgerald Anavex cash position to fund operations into 2022, says Cantor Fitzgerald 12/16/20 H.C. Wainwright Anavex price target raised to $17 from $14 at H.C. Wainwright DRIO DarioHealth $27.17 / -2.22 (-7.55%) 02/01/21 Alliance Global Partners DarioHealth downgraded to Neutral from Buy at Alliance Global Partners 08/17/20 Aegis DarioHealth initiated with a Buy at Aegis 08/13/20 Craig-Hallum DarioHealth price target raised to $17 from $8 at Craig-Hallum 06/22/20 ThinkEquity DarioHealth initiated with a Buy at ThinkEquity ENTA Enanta $50.58 / -1.1548 (-2.23%) 02/09/21 RBC Capital Enanta price target raised to $53 from $47 at RBC Capital 01/29/21 JPMorgan Enanta upgraded to Neutral with $55 target at JPMorgan 01/29/21 JPMorgan Enanta upgraded to Neutral from Underweight at JPMorgan 01/08/21 Piper Sandler Enanta remains 'significantly undervalued,' says Piper Sandler EQ Equillium $7.65 / -0.22 (-2.80%) 11/30/20 H.C. Wainwright Equillium price target lowered to $12 from $22 at H.C. Wainwright 07/14/20 H.C. Wainwright Equillium price target raised to $24 from $14 at H.C. Wainwright 07/10/20 Stifel Equillium transferred with Buy rating, $10 target at Stifel EXEL Exelixis $21.96 / -0.73 (-3.22%) 02/15/21 Piper Sandler Exelixis price target raised to $36 from $33 at Piper Sandler 01/25/21 Piper Sandler Piper says Exelixis could have 'blockbuster opportunity' with XL102 01/22/21 Piper Sandler Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler 01/20/21 William Blair Exelixis selloff on competitive concerns an 'overreaction,' says William Blair SDGR Schrodinger $104.43 / -6.46 (-5.83%) 01/25/21 BMO Capital Schrodinger price target raised to $117 from $97 at BMO Capital 11/23/20 BofA BofA upgrades Schrodinger to Buy after 'major' collaboration announcement 11/23/20 BofA Schrodinger upgraded to Buy from Neutral at BofA 10/12/20 Jefferies Schrodinger upgraded to Buy from Hold at Jefferies VCYT SIEN SDGR MTCR LLY ITOS IMRA HLIO EXEL EQ ENTA DRIO CTSO CTLT BBIO AVXL AUPH ACRS VCYT Veracyte $58.71 / -3.635 (-5.83%) 02/17/21 Veracyte sees FY21 revenue $190M-$200M, consensus $151.18M 02/17/21 Veracyte reports Q4 EPS (14c), consensus (11c) 02/03/21 Veracyte sees FY20 revenue $117M-$118.0M, consensus $114.9M 02/03/21 Veracyte sees Q4 revenue $34M-$35M, consensus $33.49M SIEN Sientra $7.70 / -0.355 (-4.41%) 02/04/21 Sientra reports preliminary Q4 revenue $22.6M, consensus $16.83M 11/09/20 Sientra sees FY20 revenue $63M-$66M, consensus $61.31M 11/09/20 Sientra reports Q3 EPS (12c), consensus (36c) SDGR Schrodinger $104.43 / -6.46 (-5.83%) 11/12/20 Schrodinger reports Q3 EPS 5c, consensus (7c) MTCR Metracrine $8.57 / -0.24 (-2.72%) 11/12/20 Metracrine reports Q3 EPS (41c), consensus ($1.41) LLY Eli Lilly $203.91 / -0.735 (-0.36%) 01/29/21 Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20 01/29/21 Eli Lilly reports Q4 EPS $2.75, consensus $2.35 01/28/21 Notable companies reporting before tomorrow's open ITOS iTeos Therapeutics $41.77 / +0.77 (+1.88%) 11/12/20 iTeos Therapeutics reports Q3 EPS (48c), consensus (36c) 09/01/20 iTeos Therapeutics reports Q2 EPS ($29.49) vs. ($36.49) a year ago IMRA Imara $12.49 / -0.45 (-3.48%) 11/05/20 Imara reports Q3 EPS (72c), consensus (80c) HLIO Helios Technologies $65.84 / -1.11 (-1.66%) 11/02/20 Helios Technologies sees FY20 revenue $485M-$495M, consensus $486.24M 11/02/20 Helios Technologies reports Q3 adjusted EPS 53c, consensus 41c EXEL Exelixis $21.96 / -0.73 (-3.22%) 02/10/21 Exelixis backs FY21 revenue view $1.15B-$1.25B, consensus $1.2B 02/10/21 Exelixis reports Q4 adjusted EPS 14c, consensus 5c 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M EQ Equillium $7.65 / -0.22 (-2.80%) 11/10/20 Equillium reports Q3 EPS (31c), consensus (40c) ENTA Enanta $50.58 / -1.1548 (-2.23%) 02/08/21 Enanta Pharmaceuticals reports Q1 EPS (41c), consensus (74c) 11/23/20 Enanta reports Q4 EPS ($1.46), consensus (95c) DRIO DarioHealth $27.17 / -2.22 (-7.55%) 01/27/21 DarioHealth sees Q4 revenue $2.12M, consensus $2.15M 11/12/20 DarioHealth reports Q3 EPS (71c), consensus (68c) CTSO CytoSorbents $9.70 / -0.44 (-4.34%) 11/04/20 CytoSorbents reports Q3 EPS (2c), consensus (9c) CTLT Catalent $112.25 / -2.87 (-2.49%) 02/02/21 Catalent raises FY21 revenue view to $3.8B-$3.95B from $3.58B-$3.78B 11/03/20 Catalent raises FY21 revenue view to $3.58B-$3.78B from $3.45B-$3.6B 11/03/20 Catalent reports Q1 adj. EPS 43c, consensus 37c 08/31/20 Catalent sees FY21 revenue $3.45B-$3.6B, consensus $3.36B BBIO BridgeBio $65.26 / -2.3001 (-3.40%) 02/25/21 BridgeBio reports Q4 EPS ($1.01), consensus (85c) 11/05/20 BridgeBio reports Q3 EPS (98c), consensus (92c) AVXL Anavex $13.01 / +0.65 (+5.26%) 02/11/21 Anavex reports Q1 EPS 12c vs. 12c last year 12/28/20 Anavex reports 2020 EPS (45c), consensus (48c) AUPH Aurinia Pharmaceuticals $14.59 / +0.015 (+0.10%) 02/24/21 Aurinia Pharmaceuticals reports Q4 EPS (5c), consensus (14c) 11/10/20 Aurinia Pharmaceuticals reports Q3 EPS (28c) vs (21c) last year ACRS Aclaris Therapeutics $21.24 / +0.52 (+2.51%) 02/25/21 Aclaris Therapeutics reports Q4 EPS (30c), consensus (27c) 11/04/20 Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c) 12 Feb 09 Feb 05 Feb 20 Jan 23 Nov 16 Sep 14 Aug 13 Aug 05 Aug 23 Jul 22 Jul 24 Jul 11 Jun 29 May 12 Mar LLY BBIO AUPH LLY Eli Lilly $203.91 / -0.735 (-0.36%) 02/10/21 Eli Lilly won't try to claw back past pay from former CFO Smiley, WSJ reports 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says BBIO BridgeBio $65.26 / -2.3001 (-3.40%) 12/11/20 GlaxoSmithKline offered $120 per share for Eidos Therapeutics, Bloomberg says AUPH Aurinia Pharmaceuticals $14.59 / +0.015 (+0.10%) 01/25/21 Aurinia's high list price 'could cause pushback,' STAT's Feuerstein says VINC VCYT SIEN SDGR MTCR LLY IMRA EXEL EQ ENTA CTLT BBIO AVXL AUPH ACRS VINC Vincera Pharma $19.19 / -0.92 (-4.57%) 09/29/20 Fly Intel: Wall Street's top stories at midday VCYT Veracyte $58.71 / -3.635 (-5.83%) 10/14/20 Fly Intel: After-Hours Movers SIEN Sientra $7.70 / -0.355 (-4.41%) 02/08/21 Fly Intel: After-Hours Movers SDGR Schrodinger $104.43 / -6.46 (-5.83%) 10/26/20 Fly Insider: Selecta, Netflix among week's notable insider trades MTCR Metracrine $8.57 / -0.24 (-2.72%) 10/01/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever LLY Eli Lilly $203.91 / -0.735 (-0.36%) 02/09/21 Fly Intel: Wall Street's top stories for Tuesday 02/09/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday IMRA Imara $12.49 / -0.45 (-3.48%) 01/06/21 Fly Intel: Wall Street's top stories for Wednesday 01/06/21 Fly Intel: Wall Street's top stories at midday EXEL Exelixis $21.96 / -0.73 (-3.22%) 02/10/21 Fly Intel: After-Hours Movers EQ Equillium $7.65 / -0.22 (-2.80%) 11/10/20 Fly Intel: After-Hours Movers 10/30/20 Fly Intel: Wall Street's top stories for Friday 10/30/20 Fly Intel: Wall Street's top stories at midday 10/30/20 Fly Intel: Pre-market Movers ENTA Enanta $50.58 / -1.1548 (-2.23%) 11/23/20 Fly Intel: After-Hours Movers CTLT Catalent $112.25 / -2.87 (-2.49%) 11/30/20 Fly Insider: Merrimack, Catalent among weeks notable insider trades 09/08/20 Tesla slides after being snubbed by S&P 500 Index BBIO BridgeBio $65.26 / -2.3001 (-3.40%) 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday AVXL Anavex $13.01 / +0.65 (+5.26%) 12/28/20 Fly Intel: Pre-market Movers 12/15/20 Fly Intel: Pre-market Movers AUPH Aurinia Pharmaceuticals $14.59 / +0.015 (+0.10%) 11/03/20 Fly Intel: Wall Street's top stories for Tuesday 11/03/20 Fly Intel: Wall Street's top stories at midday 11/02/20 Fly Intel: After-Hours Movers ACRS Aclaris Therapeutics $21.24 / +0.52 (+2.51%) 01/19/21 Fly Intel: Wall Street's top stories for Tuesday 01/19/21 Fly Intel: Wall Street's top stories at midday 01/19/21 Fly Intel: Pre-market Movers 02/25/21 10th Annual Global Healthcare Virtual Conference 03/02/21 41st Annual Healthcare Virtual Conference 03/02/21 Helios Technologies - HLIO 03/04/21 Schrodinger - SDGR 03/05/21 Vincera Pharma - VINC 03/11/21 Sientra - SIEN 03/22/21 BridgeBio - BBIO 04/27/21 Eli Lilly - LLY 03/02/21 Enanta Pharmaceuticals, Inc. SDGR LLY AUPH SDGR Schrodinger $104.43 / -6.46 (-5.83%) 10/30/20 Largest borrow rate increases among liquid names LLY Eli Lilly $203.91 / -0.735 (-0.36%) 01/15/21 Eli Lilly call volume above normal and directionally bullish 01/13/21 Early notable gainers among liquid option names on January 13th 01/11/21 Early notable gainers among liquid option names on January 11th 12/09/20 Early notable gainers among liquid option names on December 9th AUPH Aurinia Pharmaceuticals $14.59 / +0.015 (+0.10%) 02/24/21 Aurinia Pharmaceuticals options imply 18.1% move in share price post-earnings 12/24/20 Aurinia Pharmaceuticals call volume above normal and directionally bullish 11/06/20 Largest borrow rate increases among liquid names 09/10/20 Largest borrow rate increases among liquid names
Conference/Events	SVB Leerink to hold a virtual conference » 04:55 02/25/21 02/25 04:55 02/25/21 04:55 ACRS Aclaris Therapeutics $20.72 / -0.3 (-1.43%) , BBIO BridgeBio $67.57 / +1.67 (+2.53%) , HLIO Helios Technologies $66.75 / +1.46 (+2.24%) , MTCR Metracrine $8.81 / +0.21 (+2.44%) , SIEN Sientra $8.05 / -0.04 (-0.49%) , TRVI Trevi Therapeutics $2.88 / +0.05 (+1.77%) , VCYT Veracyte $62.37 / +0.88 (+1.43%) , VINC Vincera Pharma $20.21 / +1.21 (+6.37%) , CTSO CytoSorbents $10.13 / +0.04 (+0.40%) , CTLT Catalent $115.09 / +2.215 (+1.96%) , IMRA Imara $12.94 / +0.62 (+5.03%) , ITOS iTeos Therapeutics $41.00 / +1.05 (+2.63%) , LLY Eli Lilly $204.64 / +2.21 (+1.09%) , AUPH Aurinia Pharmaceuticals $14.57 / +0.21 (+1.46%) , AVXL Anavex $12.38 / +0.29 (+2.40%) , DRIO DarioHealth $28.90 / +0.15 (+0.52%) , ENTA Enanta $51.76 / +0.38 (+0.74%) , EQ Equillium $7.87 / -0.4 (-4.84%) , EXEL Exelixis $22.69 / +0.47 (+2.12%) , SDGR Schrodinger $110.89 / +2.09 (+1.92%) 10th Annual Global… 10th Annual Global Healthcare Virtual Conference will be held on February 22-26. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VINC VCYT TRVI SIEN SDGR MTCR LLY ITOS IMRA HLIO EXEL EQ ENTA DRIO CTSO CTLT BBIO AVXL AUPH ACRS VINC Vincera Pharma $20.21 / +1.21 (+6.37%) 02/24/21 Vincera Pharma to host KOL webinar on VIP152 01/07/21 Vincera Pharma changes name to Vincerx 12/23/20 Vincera Pharma comples business combination with LifeSci Acquisition VCYT Veracyte $62.37 / +0.88 (+1.43%) 02/03/21 Veracyte to acquire Decipher Biosciences for $600M 12/22/20 Bayer, Veracyte announce new collaboration to advance precision oncology 12/21/20 Veracyte receives ISO certification for QMS 12/15/20 Veracyte announces expansion of collaboration of lung cancer initiative at JNJ TRVI Trevi Therapeutics $2.88 / +0.05 (+1.77%) 02/01/21 Trevi Therapeutics appoints William Forbes as Chief Development Officer 10/21/20 Trevi Therapeutics resumes patient screening for Phase 2 trial of Haduvio SIEN Sientra $8.05 / -0.04 (-0.49%) 11/23/20 Sientra receives approval for Sientra OPUS silicone gel breast implant sizer 11/09/20 Sientra names Ron Menezes CEO, Jeffrey Nugent to retire 08/25/20 Sientra receives regulatory approval to market Opus implants in Japan SDGR Schrodinger $110.89 / +2.09 (+1.92%) 02/24/21 Schrodinger holder David Shaw sells 457.7K shares of common stock 01/19/21 David E Shaw reports 17.2% passive stake in Schrodinger 12/07/20 Schrodinger presents data from MALT1 inhibitor program at ASH 11/23/20 Schrodinger jumps 7% to $64.90 after announcing collaboration with Bristol-Myers MTCR Metracrine $8.81 / +0.21 (+2.44%) 02/16/21 Metracrine announces publication of results from Phase 1b study of MET409 01/19/21 Metracrine's MET642 granted Fast Track designation by FDA 01/05/21 Metracrine treats first patient in Phase 2a trial of MET409 with Jardiance 12/17/20 Metracrine's MET642 reports positive efficacy and safety Phase 1 results LLY Eli Lilly $204.64 / +2.21 (+1.09%) 02/23/21 Veru submits NDA for proprietary TADFIN for BPH 02/18/21 Eli Lilly, Rigel Pharmaceuticals enter exclusive license agreement for R552 02/17/21 Eli Lilly announces SURPASS-3, SURPASS-5 trials meet primary endpoints 02/10/21 Eli Lilly announces EUA for etesevimab, bamlanivimab together from FDA ITOS iTeos Therapeutics $41.00 / +1.05 (+2.63%) 11/12/20 iTeos Therapeutics appoints Matthew Roden to board of directors IMRA Imara $12.94 / +0.62 (+5.03%) 01/20/21 Imara appoints Kenneth Atttie as Chief Medical Officer 01/06/21 Imara reports Phase 2a trial results of IMR-687 in SCD 12/07/20 Imara presents IMR-687 Phase 2a OLE case reports 11/30/20 Imara to present clinical data on IMR-687 at ASH Annual Meeting HLIO Helios Technologies $66.75 / +1.46 (+2.24%) 01/21/21 Helios Technologies to acquire BJN Technologies, terms undisclosed 10/12/20 Helios Technologies to acquire Balboa Water Group for $218.5M EXEL Exelixis $22.69 / +0.47 (+2.12%) 02/14/21 Exelixis announces Phase 2 results for CABOMETYX in metastatic PRCC 02/12/21 Exelixis announces 'positive' final data for Phase 1 cabozantinib trial 02/08/21 Exelixis to announce results from Cabometyx retrospective analysis 01/25/21 Exelixis announces initiation of XL102 trial EQ Equillium $7.87 / -0.4 (-4.84%) 02/12/21 Equillium presents 'positive' interim clinical data on Itolizumab trial in aGVHD 02/09/21 Equillium appoints Katherine Xu to board of directors 12/21/20 Equillium appoints Dolca Thomas as CMO, EVP, R&D 12/07/20 Equillium presents translational data on itolizumab ENTA Enanta $51.76 / +0.38 (+0.74%) 01/08/21 Enanta says 'meaningful progress' made on pipeline in 2020 09/14/20 Enanta initiates Phase 1 clinical study of EDP-297 08/28/20 Enanta to present data from hepatitis B virus, NASH programs at EASL DRIO DarioHealth $28.90 / +0.15 (+0.52%) 01/27/21 DarioHealth to acquire Upright Technologies for $29.5M in stock, $1.5M in cash 12/22/20 DarioHealth enters into agreement with Presbyterian Medical Services 11/24/20 DarioHealth to offer therapeutics solution to Fortune 500 technology companies 09/21/20 DarioHealth, HMC HealthWorks announce partnership agreement CTSO CytoSorbents $10.13 / +0.04 (+0.40%) 01/19/21 CytoSorb approved in Korea for all EU approved indications 01/12/21 Health Canada authorizes CytoSorb for use in hospitalized COVID-19 patients 01/04/21 CytoSorbents gets Medical Device Authorization for CytoSorb in COVID-19 patients 12/09/20 CytoSorbents announces publication of CytoSorb matched analysis CTLT Catalent $115.09 / +2.215 (+1.96%) 02/16/21 Moderna provides supply update for U.S. COVID-19 vaccines 02/02/21 Catalent reports Q2 adjusted EPS 63c, consensus 55c 01/13/21 Catalent to acquire manufacturing operations from Acorda Therapeutics 01/13/21 Acorda to sell Inbrija manufacturing operations to Catalent for $80M BBIO BridgeBio $67.57 / +1.67 (+2.53%) 02/19/21 BridgeBio, ML Bio Solutions dose first patient in Phase 2 trial of BBP-418 02/02/21 BridgeBio doses first patient in Phase 1/2 trial of BBP-681 for malformations 01/26/21 BridgeBio completes acquisition of Eidos Therapeutics 01/19/21 BridgeBio and Eidos' stockholders approve acquisition AVXL Anavex $12.38 / +0.29 (+2.40%) 02/11/21 Anavex sees sufficient cash runway for up to three years 02/04/21 Anavex trading resumes 02/04/21 Anavex trading halted, volatility trading pause 02/03/21 Anavex trading resumes AUPH Aurinia Pharmaceuticals $14.57 / +0.21 (+1.46%) 01/24/21 FDA approves Aurinia's LUPKYNIS for adult patients with active lupus nephritis 01/22/21 Aurinia Pharmaceuticals trading halted, news pending 12/17/20 Aurinia Pharmaceuticals enters voclosporin license agreement with Otsuka 12/15/20 Aurinia, Lonza strike exclusive pact for voclosporin manufacturing capacity ACRS Aclaris Therapeutics $20.72 / -0.3 (-1.43%) 02/22/21 Aclaris Therapeutics trading resumes 02/22/21 Aclaris Therapeutics trading halted, volatility trading pause 01/21/21 Aclaris gets orphan drug designation in cryopyrin-associated periodic syndrome 01/19/21 Aclaris Therapeutics trading resumes ACRS BBIO HLIO MTCR SIEN TRVI VCYT VINC CTSO CTLT IMRA ITOS LLY AUPH AVXL DRIO ENTA EQ EXEL SDGR ACRS Aclaris Therapeutics $20.72 / -0.3 (-1.43%) 02/02/21 Cantor Fitzgerald Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald 01/19/21 William Blair Aclaris has potential in range of 'blockbuster indications,' says William Blair BBIO BridgeBio $67.57 / +1.67 (+2.53%) 02/22/21 JPMorgan BridgeBio reinstated with an Overweight at JPMorgan 02/09/21 Fly Intel: Top five analyst initiations 02/09/21 Goldman Sachs BridgeBio reinstated with a Buy at Goldman Sachs 01/11/21 H.C. Wainwright BridgeBio price target raised to $87 from $64 at H.C. Wainwright HLIO Helios Technologies $66.75 / +1.46 (+2.24%) 10/12/20 Baird Helios Technologies upgraded to Outperform from Neutral at Baird 05/29/20 Morgan Stanley Morgan Stanley upgrades Helios to Equal Weight following underperformance 05/29/20 Morgan Stanley Helios Technologies upgraded to Equal Weight from Underweight at Morgan Stanley 03/27/20 Truist Helios Technologies price target lowered to $36 from $45 at SunTrust MTCR Metracrine $8.81 / +0.21 (+2.44%) 10/12/20 Canaccord Metracrine initiated with a Buy at Canaccord 10/12/20 Jefferies Metracrine initiated with a Buy at Jefferies 10/12/20 RBC Capital Metracrine initiated with an Outperform at RBC Capital SIEN Sientra $8.05 / -0.04 (-0.49%) 02/05/21 Canaccord Sientra price target raised to $8 from $6 at Canaccord 10/08/20 Stifel Stifel sees upside potential for Sientra after survey of aesthetics doctors 06/11/20 Maxim Sientra price target raised to $8 from $5 at Maxim 03/12/20 Craig-Hallum Sientra price target lowered to $9 from $14 at Craig-Hallum TRVI Trevi Therapeutics $2.88 / +0.05 (+1.77%) 07/13/20 Stifel Trevi Therapeutics price target lowered to $10 from $14 at Stifel VCYT Veracyte $62.37 / +0.88 (+1.43%) 02/18/21 Needham Veracyte assumed with a Buy at Needham 02/08/21 SVB Leerink Veracyte price target raised to $83 from $40 at SVB Leerink 01/27/21 Truist Veracyte initiated with a Buy at Truist 12/17/20 Lake Street Veracyte price target raised to $60 from $40 at Lake Street VINC Vincera Pharma $20.21 / +1.21 (+6.37%) 01/06/21 Chardan Vincera Pharma initiated with a Buy at Chardan CTSO CytoSorbents $10.13 / +0.04 (+0.40%) 01/04/21 B. Riley CytoSorbents price target raised to $17 from $16 at B. Riley Securities 09/01/20 SVB Leerink CytoSorbents initiated with an Outperform at SVB Leerink 08/25/20 B. Riley CytoSorbents 29% pullback from highs a buying opportunity, says B. Riley FBR 06/02/20 B. Riley CytoSorbents gaining relevance as COVID-19 treatment, says B. Riley FBR CTLT Catalent $115.09 / +2.215 (+1.96%) 02/03/21 UBS Catalent price target raised to $135 from $115 at UBS 02/03/21 RBC Capital Catalent price target raised to $137 from $125 at RBC Capital 01/08/21 JPMorgan Catalent price target raised to $130 from $110 at JPMorgan 01/04/21 Stephens Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens IMRA Imara $12.94 / +0.62 (+5.03%) 01/06/21 SVB Leerink Imara selloff a potential buying opportunity, says SVB Leerink 08/17/20 Fly Intel: Top five analyst upgrades 08/17/20 Citi Imara upgraded to Buy from Neutral at Citi 06/30/20 Citi Imara downgraded to Neutral from Buy at Citi ITOS iTeos Therapeutics $41.00 / +1.05 (+2.63%) 10/07/20 Baird iTeos Therapeutics initiated with an Outperform at Baird 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/01/20 Piper Sandler iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler 08/18/20 SVB Leerink SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform LLY Eli Lilly $204.64 / +2.21 (+1.09%) 02/18/21 H.C. Wainwright Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright 02/18/21 Piper Sandler Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler 02/12/21 Cowen Eli Lilly price target raised to $235 from $195 at Cowen 02/08/21 SVB Leerink AbCellera price target raised to $52 from $45 at SVB Leerink AUPH Aurinia Pharmaceuticals $14.57 / +0.21 (+1.46%) 01/26/21 RBC Capital Aurinia Pharmaceuticals price target raised to $28 from $20 at RBC Capital 01/26/21 Cantor Fitzgerald Aurinia Pharmaceuticals price target raised to $34 from $27 at Cantor Fitzgerald 01/25/21 Oppenheimer Aurinia Pharmaceuticals price target raised to $28 from $20 at Oppenheimer 01/25/21 H.C. Wainwright Aurinia Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright AVXL Anavex $12.38 / +0.29 (+2.40%) 02/24/21 Cantor Fitzgerald Anavex price target raised to $25 from $10 at Cantor Fitzgerald 02/23/21 Cantor Fitzgerald Anavex price target raised to $25 from $10 at Cantor Fitzgerald 12/29/20 Cantor Fitzgerald Anavex cash position to fund operations into 2022, says Cantor Fitzgerald 12/16/20 H.C. Wainwright Anavex price target raised to $17 from $14 at H.C. Wainwright DRIO DarioHealth $28.90 / +0.15 (+0.52%) 02/01/21 Alliance Global Partners DarioHealth downgraded to Neutral from Buy at Alliance Global Partners 08/17/20 Aegis DarioHealth initiated with a Buy at Aegis 08/13/20 Craig-Hallum DarioHealth price target raised to $17 from $8 at Craig-Hallum 06/22/20 ThinkEquity DarioHealth initiated with a Buy at ThinkEquity ENTA Enanta $51.76 / +0.38 (+0.74%) 02/09/21 RBC Capital Enanta price target raised to $53 from $47 at RBC Capital 01/29/21 JPMorgan Enanta upgraded to Neutral with $55 target at JPMorgan 01/29/21 JPMorgan Enanta upgraded to Neutral from Underweight at JPMorgan 01/08/21 Piper Sandler Enanta remains 'significantly undervalued,' says Piper Sandler EQ Equillium $7.87 / -0.4 (-4.84%) 11/30/20 H.C. Wainwright Equillium price target lowered to $12 from $22 at H.C. Wainwright 07/14/20 H.C. Wainwright Equillium price target raised to $24 from $14 at H.C. Wainwright 07/10/20 Stifel Equillium transferred with Buy rating, $10 target at Stifel EXEL Exelixis $22.69 / +0.47 (+2.12%) 02/15/21 Piper Sandler Exelixis price target raised to $36 from $33 at Piper Sandler 01/25/21 Piper Sandler Piper says Exelixis could have 'blockbuster opportunity' with XL102 01/22/21 Piper Sandler Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler 01/20/21 William Blair Exelixis selloff on competitive concerns an 'overreaction,' says William Blair SDGR Schrodinger $110.89 / +2.09 (+1.92%) 01/25/21 BMO Capital Schrodinger price target raised to $117 from $97 at BMO Capital 11/23/20 BofA BofA upgrades Schrodinger to Buy after 'major' collaboration announcement 11/23/20 BofA Schrodinger upgraded to Buy from Neutral at BofA 10/12/20 Jefferies Schrodinger upgraded to Buy from Hold at Jefferies VCYT SIEN SDGR MTCR LLY ITOS IMRA HLIO EXEL EQ ENTA DRIO CTSO CTLT BBIO AVXL AUPH ACRS VCYT Veracyte $62.37 / +0.88 (+1.43%) 02/17/21 Veracyte sees FY21 revenue $190M-$200M, consensus $151.18M 02/17/21 Veracyte reports Q4 EPS (14c), consensus (11c) 02/03/21 Veracyte sees FY20 revenue $117M-$118.0M, consensus $114.9M 02/03/21 Veracyte sees Q4 revenue $34M-$35M, consensus $33.49M SIEN Sientra $8.05 / -0.04 (-0.49%) 02/04/21 Sientra reports preliminary Q4 revenue $22.6M, consensus $16.83M 11/09/20 Sientra sees FY20 revenue $63M-$66M, consensus $61.31M 11/09/20 Sientra reports Q3 EPS (12c), consensus (36c) SDGR Schrodinger $110.89 / +2.09 (+1.92%) 11/12/20 Schrodinger reports Q3 EPS 5c, consensus (7c) MTCR Metracrine $8.81 / +0.21 (+2.44%) 11/12/20 Metracrine reports Q3 EPS (41c), consensus ($1.41) LLY Eli Lilly $204.64 / +2.21 (+1.09%) 01/29/21 Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20 01/29/21 Eli Lilly reports Q4 EPS $2.75, consensus $2.35 01/28/21 Notable companies reporting before tomorrow's open ITOS iTeos Therapeutics $41.00 / +1.05 (+2.63%) 11/12/20 iTeos Therapeutics reports Q3 EPS (48c), consensus (36c) 09/01/20 iTeos Therapeutics reports Q2 EPS ($29.49) vs. ($36.49) a year ago IMRA Imara $12.94 / +0.62 (+5.03%) 11/05/20 Imara reports Q3 EPS (72c), consensus (80c) HLIO Helios Technologies $66.75 / +1.46 (+2.24%) 11/02/20 Helios Technologies sees FY20 revenue $485M-$495M, consensus $486.24M 11/02/20 Helios Technologies reports Q3 adjusted EPS 53c, consensus 41c EXEL Exelixis $22.69 / +0.47 (+2.12%) 02/10/21 Exelixis backs FY21 revenue view $1.15B-$1.25B, consensus $1.2B 02/10/21 Exelixis reports Q4 adjusted EPS 14c, consensus 5c 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M EQ Equillium $7.87 / -0.4 (-4.84%) 11/10/20 Equillium reports Q3 EPS (31c), consensus (40c) ENTA Enanta $51.76 / +0.38 (+0.74%) 02/08/21 Enanta Pharmaceuticals reports Q1 EPS (41c), consensus (74c) 11/23/20 Enanta reports Q4 EPS ($1.46), consensus (95c) DRIO DarioHealth $28.90 / +0.15 (+0.52%) 01/27/21 DarioHealth sees Q4 revenue $2.12M, consensus $2.15M 11/12/20 DarioHealth reports Q3 EPS (71c), consensus (68c) CTSO CytoSorbents $10.13 / +0.04 (+0.40%) 11/04/20 CytoSorbents reports Q3 EPS (2c), consensus (9c) CTLT Catalent $115.09 / +2.215 (+1.96%) 02/02/21 Catalent raises FY21 revenue view to $3.8B-$3.95B from $3.58B-$3.78B 11/03/20 Catalent raises FY21 revenue view to $3.58B-$3.78B from $3.45B-$3.6B 11/03/20 Catalent reports Q1 adj. EPS 43c, consensus 37c 08/31/20 Catalent sees FY21 revenue $3.45B-$3.6B, consensus $3.36B BBIO BridgeBio $67.57 / +1.67 (+2.53%) 11/05/20 BridgeBio reports Q3 EPS (98c), consensus (92c) AVXL Anavex $12.38 / +0.29 (+2.40%) 02/11/21 Anavex reports Q1 EPS 12c vs. 12c last year 12/28/20 Anavex reports 2020 EPS (45c), consensus (48c) AUPH Aurinia Pharmaceuticals $14.57 / +0.21 (+1.46%) 02/24/21 Aurinia Pharmaceuticals reports Q4 EPS (5c), consensus (14c) 11/10/20 Aurinia Pharmaceuticals reports Q3 EPS (28c) vs (21c) last year ACRS Aclaris Therapeutics $20.72 / -0.3 (-1.43%) 11/04/20 Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c) 12 Feb 09 Feb 05 Feb 20 Jan 23 Nov 16 Sep 14 Aug 13 Aug 05 Aug 23 Jul 22 Jul 24 Jul 11 Jun 29 May 12 Mar LLY BBIO AUPH LLY Eli Lilly $204.64 / +2.21 (+1.09%) 02/10/21 Eli Lilly won't try to claw back past pay from former CFO Smiley, WSJ reports 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says BBIO BridgeBio $67.57 / +1.67 (+2.53%) 12/11/20 GlaxoSmithKline offered $120 per share for Eidos Therapeutics, Bloomberg says AUPH Aurinia Pharmaceuticals $14.57 / +0.21 (+1.46%) 01/25/21 Aurinia's high list price 'could cause pushback,' STAT's Feuerstein says VINC VCYT SIEN SDGR MTCR LLY IMRA EXEL EQ ENTA CTLT BBIO AVXL AUPH ACRS VINC Vincera Pharma $20.21 / +1.21 (+6.37%) 09/29/20 Fly Intel: Wall Street's top stories at midday VCYT Veracyte $62.37 / +0.88 (+1.43%) 10/14/20 Fly Intel: After-Hours Movers SIEN Sientra $8.05 / -0.04 (-0.49%) 02/08/21 Fly Intel: After-Hours Movers SDGR Schrodinger $110.89 / +2.09 (+1.92%) 10/26/20 Fly Insider: Selecta, Netflix among week's notable insider trades MTCR Metracrine $8.81 / +0.21 (+2.44%) 10/01/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever LLY Eli Lilly $204.64 / +2.21 (+1.09%) 02/09/21 Fly Intel: Wall Street's top stories for Tuesday 02/09/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday IMRA Imara $12.94 / +0.62 (+5.03%) 01/06/21 Fly Intel: Wall Street's top stories for Wednesday 01/06/21 Fly Intel: Wall Street's top stories at midday EXEL Exelixis $22.69 / +0.47 (+2.12%) 02/10/21 Fly Intel: After-Hours Movers EQ Equillium $7.87 / -0.4 (-4.84%) 11/10/20 Fly Intel: After-Hours Movers 10/30/20 Fly Intel: Wall Street's top stories for Friday 10/30/20 Fly Intel: Wall Street's top stories at midday 10/30/20 Fly Intel: Pre-market Movers ENTA Enanta $51.76 / +0.38 (+0.74%) 11/23/20 Fly Intel: After-Hours Movers CTLT Catalent $115.09 / +2.215 (+1.96%) 11/30/20 Fly Insider: Merrimack, Catalent among weeks notable insider trades 09/08/20 Tesla slides after being snubbed by S&P 500 Index BBIO BridgeBio $67.57 / +1.67 (+2.53%) 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday AVXL Anavex $12.38 / +0.29 (+2.40%) 12/28/20 Fly Intel: Pre-market Movers 12/15/20 Fly Intel: Pre-market Movers AUPH Aurinia Pharmaceuticals $14.57 / +0.21 (+1.46%) 11/03/20 Fly Intel: Wall Street's top stories for Tuesday 11/03/20 Fly Intel: Wall Street's top stories at midday 11/02/20 Fly Intel: After-Hours Movers ACRS Aclaris Therapeutics $20.72 / -0.3 (-1.43%) 01/19/21 Fly Intel: Wall Street's top stories for Tuesday 01/19/21 Fly Intel: Wall Street's top stories at midday 01/19/21 Fly Intel: Pre-market Movers 02/25/21 10th Annual Global Healthcare Virtual Conference 03/02/21 41st Annual Healthcare Virtual Conference 03/02/21 Helios Technologies - HLIO 03/04/21 Schrodinger - SDGR 03/05/21 Vincera Pharma - VINC 04/27/21 Eli Lilly - LLY 03/02/21 Enanta Pharmaceuticals, Inc. SDGR LLY AUPH SDGR Schrodinger $110.89 / +2.09 (+1.92%) 10/30/20 Largest borrow rate increases among liquid names LLY Eli Lilly $204.64 / +2.21 (+1.09%) 01/15/21 Eli Lilly call volume above normal and directionally bullish 01/13/21 Early notable gainers among liquid option names on January 13th 01/11/21 Early notable gainers among liquid option names on January 11th 12/09/20 Early notable gainers among liquid option names on December 9th AUPH Aurinia Pharmaceuticals $14.57 / +0.21 (+1.46%) 02/24/21 Aurinia Pharmaceuticals options imply 18.1% move in share price post-earnings 12/24/20 Aurinia Pharmaceuticals call volume above normal and directionally bullish 11/06/20 Largest borrow rate increases among liquid names 09/10/20 Largest borrow rate increases among liquid names

On The Fly

News and insights, exclusive to thefly.com

09:55	Fly Intel: Top five analyst initiations»
09:54	Fly Intel: Top five analyst downgrades»
09:54	Fly Intel: Top five analyst upgrades»
20:25	Notable companies reporting before tomorrow's open»
13:27	Notable companies reporting before tomorrow's open»

View all On The Fly Stories »

Upcoming
Events (10)

NPCE	NeuroPace - NPCE
	Annual Clinical Genetics Virtual Meeting of ACMG
FOUR ...	Technology Enabling the Restaurant Recovery
	Texas A&M Bitcoin Virtual Conference 2021
DE	Deere
ONCR	FuboTV
WSR	Whitestone REIT
MGTA	Magenta Therapeutics
INO	FuboTV
CFG	Citizens Financial - CFG

View all of today’s events »

Today’s
Syndicate (8)

AKYA	IPO
BMEA	IPO
RXRX	IPO
BALY	Secondary
MAXN	Secondary
PHX	Spot Secondary
SPNE	Spot Secondary
SYBX	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial